Document is current
Any future updates will be listed below
-
Authors
Gondran, Camille
Dumas, Pierre-Yves
Bérard, Emilie
Bidet, Audrey https://orcid.org/0000-0003-0992-8377
Delabesse, Eric https://orcid.org/0000-0002-0928-0753
Tavitian, Suzanne
Leguay, Thibaut
Huguet, Françoise
Borel, Cécile
Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Vergez, François https://orcid.org/0000-0002-0063-4404
Vial, Jean-Philippe https://orcid.org/0000-0003-3109-0064
Rieu, Jean Baptiste
Lechevalier, Nicolas https://orcid.org/0000-0003-1959-7938
Luquet, Isabelle
Canali, Alban https://orcid.org/0000-0002-1609-3307
Klein, Emilie
Sarry, Audrey
de Grande, Anne-Charlotte
Pigneux, Arnaud
Récher, Christian https://orcid.org/0000-0002-3332-4525
Largeaud, Laetitia
Bertoli, Sarah https://orcid.org/0000-0003-1084-2781
- License Information
-
More Information
Article History
Received: 2 April 2024
Revised: 10 May 2024
Accepted: 14 May 2024
First Online: 31 May 2024
Competing interests
: SB declares a consulting or advisory role with Abbvie, Astellas, BMS-Celgene, Jazz Pharmaceuticals as well as Servier and received travel grants from Abbvie and Pfizer. CR declares a consulting or advisory role with Abbvie, Amgen, Astellas, BMS, Boehringer, Jazz Pharmaceuticals as well as Servier, received research funding from Abbvie, Amgen, Astellas, BMS, Iqvia and Jazz Pharmaceuticals, and support for attending meetings and/or travel from Abbvie, Novartis and Servier. AP declares a consulting or advisory role with Astellas, BMS, Servier, Abbvie, Gilead, Jazz Pharmaceuticals, Novartis, Pfizer, received research funding from Astellas, BMS, Roche, Servier and support for attending meetings and/or travel from Servier, Abbvie. FV: research grants from Pierre Fabre and Roche; advisor for Astellas and Amgen. FH: consultancy Novartis, Pfizer, Incyte, honoraria Amgen, Servier; Isabelle Luquet: advisory role for Jazz Pharmaceuticals. All other authors declare no competing interests.
: The cohort has been approved by the national ethical authorities (CCTIRS (ref 15.319) and CNIL (ref 915285)). All patients included in the DATAML cohort received and signed the information notice to express their non-opposition for the use of their data for research.
